Contriving a novel multi-epitope subunit vaccine from Plasmodium falciparum vaccine candidates against malaria

Simple item page
dc.contributor.authorMamudu, COen_US
dc.contributor.authorIheagwam, FNen_US
dc.contributor.authorOkafor, EOen_US
dc.contributor.authorDokunmu, TMen_US
dc.contributor.authorOgunlana, OOen_US
dc.date.accessioned2024-11-30T11:21:19Z
dc.date.available2024-11-30T11:21:19Z
dc.date.issued2024-09
dc.description.abstractIn this study, immunoinformatics strategies were used to design a subunit vaccine against malaria from immunogenic regions of three Plasmodium falciparum surface antigens; liver stage antigen 3-C (V750-K1433), merozoite surface antigen 180 truncate-4 (A805-P1093), and merozoite surface protein 10 region 1 (D29-N188). A multi-epitope subunit vaccine construct (VC) was designed from immunodominant B- and T-cell epitopes followed by structure prediction, evaluation, and validation. Toll-like receptors (TLRs) 2 and 4 were docked with the VC. Their complexes’ molecular dynamics, immune stimulation, codon optimization, and in silico cloning of the VC were simulated. The VC is a 49.2 kDa antigenic and nonallergenic protein, comprised of 26% ?-helix, 7% ?-strand, 66% coil. The immune simulation test showed that the vaccine could provoke adaptive immune responses, and molecular docking tests showed that it interacts strongly with TLR-2 (?945.1 kcal/mol) and TLR-4 (?919.8 kcal/mol) to form complexes of high stability that hardly deform. The guanine-cytosine content and codon adaptation index of the VC were 42.94 and 0.99 after codon optimization. Escherichia coli pET-28a(+) was identified as the best vector for optimal gene expression. In conclusion, the study reveals that the VC shows promising results in neutralizing falciparum malaria.en_US
dc.identifier.affiliationsDepartment of Biochemistry, Covenant University, Ota, Nigeria; Covenant Applied Informatics and Communication Africa Centre of Excellence, Ota, Nigeriaen_US
dc.identifier.affiliationsDepartment of Biochemistry, Covenant University, Ota, Nigeria; Covenant University Public Health and Wellbeing Research Cluster, Ota, Nigeriaen_US
dc.identifier.affiliationsDepartment of Biochemistry, Covenant University, Ota, Nigeria; Covenant University Bioinformatics Research, Ota, Nigeriaen_US
dc.identifier.affiliationsDepartment of Biochemistry, Covenant University, Ota, Nigeria; Covenant Applied Informatics and Communication Africa Centre of Excellence, Ota, Nigeriaen_US
dc.identifier.affiliationsDepartment of Biochemistry, Covenant University, Ota, Nigeria; Covenant Applied Informatics and Communication Africa Centre of Excellence, Ota, Nigeriaen_US
dc.identifier.citationMamudu CO, Iheagwam FN, Okafor EO, Dokunmu TM, Ogunlana OO. Contriving a novel multi-epitope subunit vaccine from Plasmodium falciparum vaccine candidates against malaria. Journal of Applied Pharmaceutical Science. 2024 Sept; 14(9): 156-168en_US
dc.identifier.issn2231-3354
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/237694
dc.languageenen_US
dc.publisherOpen Science Publishers LLPen_US
dc.relation.issuenumber9en_US
dc.relation.volume14en_US
dc.source.urihttps://doi.org/10.7324/JAPS.2024.162649en_US
dc.subjectEpitopesen_US
dc.subjectimmunoinformaticsen_US
dc.subjectmalariaen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectvaccine construct.en_US
dc.titleContriving a novel multi-epitope subunit vaccine from Plasmodium falciparum vaccine candidates against malariaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
japs2024v14n9p156.pdf
Size:
3.24 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Applied Pharmaceutical Science (JAPS)